We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Affordable POC Tests to Improve Early Cancer Detection in Low-Resource Settings

By LabMedica International staff writers
Posted on 31 Oct 2023
Print article
Image: The new research center will develop affordable global health technologies for early cancer detection (Photo courtesy of 123RF)
Image: The new research center will develop affordable global health technologies for early cancer detection (Photo courtesy of 123RF)

Cancer ranks as the first or second leading cause of early death in 134 out of 183 countries. Forecasts suggest that the global rate of cancer cases will surge by 50% between 2018 and 2040. This increase is expected to be more pronounced in countries with fewer resources and inadequate healthcare infrastructure to manage cancer effectively. While early detection and proper treatment can cure most types of cancer, existing diagnostic tests are often too complex or costly to be used in basic healthcare settings, especially in areas with limited medical services. Now, new point-of-care (POC) technologies for early cancer detection aim to bring healthcare services closer to the patient, making treatment timelier and more accessible, which could enhance outcomes in the long run.

Rice University (Houston, TX, USA) is leading a multinational collaboration, involving engineers, cancer specialists, and global health experts from three different continents. The research group has received a grant for up to five years from the National Institutes of Health to set up a leading research facility within the Texas Medical Center. The focus will be on creating cost-effective POC technologies for early cancer detection in both the United States and other nations lacking sufficient healthcare infrastructure. Named the Center for Innovation and Translation of POC Technologies for Equitable Cancer Care (CITEC), the center will operate under the umbrella of the Rice360 Institute for Global Health Technologies. Funded initially by a USD 1.3 million grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the center could receive up to USD 6.5 million over the next five years. CITEC will primarily focus on the development of POC diagnostics for oral, cervical, and gastrointestinal cancers.

“CITEC will identify needed technologies, accelerate their development, evaluate their performance and impact in diverse settings and train local users and technology developers to create and disseminate more equitable POC technologies,” said Sharmila Anandasabapathy is vice president of global health at Baylor College of Medicine.

Related Links:
Rice University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.